Amgen Owes Lindis $50 Million Patent Royalty Over Blincyto (1)

Amgen Inc. must pay Lindis Biotech GmbH $50.3 million after a federal jury in Delaware found its Blincyto cancer drug infringes two patents for methods of administering a leukemia treatment.

Blincyto’s label actively induces health-care providers to administer it in a manner that infringes Lindis’ US Patent Nos. 10,071,158 and 8,709,421, according to a verdict issued Tuesday in the US District Court for the District of Delaware after a jury trial that began Dec. 9. The public version of the verdict sheet was docketed Wednesday morning.

Jurors upheld the patents’ validity and found the infringement was willful, which gives ...